Cargando…
Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis
PURPOSE: The extent to which efficacy of the HER2 antibody Trastuzumab in brain metastases is limited by access of antibody to brain lesions remains a question of significant clinical importance. We investigated the uptake and distribution of trastuzumab in brain and mammary fat pad grafts of HER2-p...
Autores principales: | Lewis Phillips, Gail D., Nishimura, Merry C., Lacap, Jennifer Arca, Kharbanda, Samir, Mai, Elaine, Tien, Janet, Malesky, Kimberly, Williams, Simon P., Marik, Jan, Phillips, Heidi S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495871/ https://www.ncbi.nlm.nih.gov/pubmed/28493046 http://dx.doi.org/10.1007/s10549-017-4279-4 |
Ejemplares similares
-
Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics
por: Lewis Phillips, Gail, et al.
Publicado: (2021) -
Activity of trastuzumab emtansine (T-DM1) in 3D cell culture
por: Boyer, Jean Zheng, et al.
Publicado: (2021) -
HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014) -
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013) -
Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
por: Fiascarelli, Alessio, et al.
Publicado: (2023)